Full Press Release Details
LA JOLLA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s president and chief business officer, will present at two upcoming investor conferences in November 2019.
| Event: | Stifel 2019 Healthcare Conference | |
| Date: | Tuesday, November 19, 2019 | |
| Time: | 10:55 AM Eastern Time | 7:55 AM Pacific Time | |
| Location: | Lotte New York Palace Hotel in New York | |
| Event: | Jefferies 2019 London Healthcare Conference | |
| Date: | Thursday, November 21, 2019 | |
| Time: | 2:00 PM Greenwich Mean Time | 9:00 AM Eastern Time | 6:00 AM Pacific Time | |
| Location: | Waldorf Hilton Hotel in London |
Live webcasts of both presentations will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/. Replays will be available for 30 days following each webcast.
Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need.
Equillium’s initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically-validated therapeutic that has demonstrated a favorable safety and tolerability profile. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. Equillium believes that itolizumab has the potential to be a best-in-class disease modifying therapeutic and is advancing itolizumab into clinical development in the following severe immuno-inflammatory disorders: uncontrolled asthma, acute graft-versus-host disease, and lupus nephritis. For more information, visit www.equilliumbio.com.
Canale Communications